Earnings summaries and quarterly performance for Mirum Pharmaceuticals.
Executive leadership at Mirum Pharmaceuticals.
Board of directors at Mirum Pharmaceuticals.
Research analysts who have asked questions during Mirum Pharmaceuticals earnings calls.
DL
David Lebowitz
Citigroup Inc.
4 questions for MIRM
Also covers: ALNY, ARWR, ASND +11 more
Gavin Clark-Gartner
Evercore ISI
4 questions for MIRM
Also covers: ACRS, ARGX, ASND +11 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for MIRM
Also covers: ALKS, ALNY, AMRN +23 more
Ryan Deschner
Raymond James Financial
4 questions for MIRM
Also covers: APLS, ARDX, ARSP +7 more
JW
Jon Wolleben
Citizen JMP
2 questions for MIRM
Also covers: BCRX, CLSD, MDGL +3 more
MU
Michael Ulz
Morgan Stanley
2 questions for MIRM
Also covers: ALNY, ARWR, FATE +8 more
Ryan Mcelroy
Leerink Partners
2 questions for MIRM
Also covers: BBIO, RGNX
Abdullah
J.P. Morgan
1 question for MIRM
Brian Skorney
Robert W. Baird & Co.
1 question for MIRM
Also covers: ABUS, CRNX, MRNS +6 more
Catherine Okoukoni
Citizens JMP
1 question for MIRM
Also covers: ALT, CRNX, KALV +2 more
DG
Dae Gon Ha
Stifel
1 question for MIRM
Also covers: ABEO, BEAM, CRBP +10 more
GC
Gavin Clark-Gardner
Evercore
1 question for MIRM
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
1 question for MIRM
Also covers: ALT, BCRX, CLSD +5 more
Joseph Thome
TD Cowen
1 question for MIRM
Also covers: ALKS, AMLX, ARDX +12 more
JS
Josh Schimmer
Cantor Fitzgerald
1 question for MIRM
Also covers: BBIO, BYSI, CRNX +3 more
JS
Joshua Schimmer
Evercore ISI
1 question for MIRM
Also covers: KRYS, NBIX, SPRY
M
Mark
Stifel
1 question for MIRM
R
Rohit
Morgan Stanley
1 question for MIRM
Rohit Bhasin
Morgan Stanley
1 question for MIRM
Also covers: GUTS, VKTX
R
Ryan
B. Riley
1 question for MIRM
Also covers: BEEM, PATH, PPG
Selena Zhang
Morgan Stanley
1 question for MIRM
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABSI, BSEM, CGEN +24 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABUS, ARDX, ENTA +6 more
Timur Ivannikov
Raymond James
1 question for MIRM
Also covers: APLS, GLMD, IFRX
Recent press releases and 8-K filings for MIRM.
Mirum Pharmaceuticals Files Patent Infringement Suits Against Generic Drugmakers
MIRM
Legal Proceedings
- Mirum Pharmaceuticals, Inc. received Paragraph IV Certification Notice Letters in November 2025 from Sandoz, Inc., Annora Pharma Private Limited, Zydus Lifesciences Global FZE, and Zenara Pharma Private Limited, indicating their intent to seek approval for generic versions of its drug Livmarli® (maralixibat).
- On December 19, 2025, Mirum filed patent infringement lawsuits against these companies in the United States District Court for the District of Delaware.
- These lawsuits allege infringement of Mirum's Orange Book listed patents for Livmarli® and result in a 30-month stay, preventing the FDA from issuing final approval for the generic Abbreviated New Drug Applications (ANDAs).
5 days ago
Mirum Pharmaceuticals Announces Additional Private Placement Financing
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals entered into a subscription agreement with TCGX for a private placement of 1,000,000 shares of its common stock at $68.48 per share, generating approximately $68.5 million in gross proceeds.
- This financing, combined with a previous $200 million private placement announced earlier this month, is intended to fund clinical development and commercial activities following the proposed acquisition of Bluejay Therapeutics.
- Both private placements are expected to close concurrently with the Bluejay acquisition, which is anticipated in the first quarter of 2026, subject to regulatory approval and other customary closing conditions.
6 days ago
Mirum Pharmaceuticals announces acquisition of BlueJ Therapeutics
MIRM
M&A
New Projects/Investments
Guidance Update
- Mirum Pharmaceuticals has entered into a definitive agreement to acquire BlueJ Therapeutics for $250 million in cash and $370 million in Mirum stock, with up to $200 million in sales-based milestone payments.
- The acquisition adds tegovibart, a late-stage asset for chronic hepatitis delta virus, which has demonstrated 100% virologic response in Phase II studies and holds FDA Breakthrough Therapy designation.
- This transaction is expected to close in the first quarter of 2026 and is projected to increase Mirum's rare disease portfolio revenue potential to over $4 billion.
- Mirum secured $200 million in private placement financing to fund the acquisition and anticipates becoming cash flow positive in 2027.
- Tegovibart's Phase III program is ongoing, with interim data from Azure One expected in Q2 2026 and final data from Azure One and Four in H2 2026, targeting a BLA submission in the first half of 2027.
Dec 8, 2025, 1:30 PM
Mirum Pharmaceuticals to Acquire BlueJ Therapeutics
MIRM
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Mirum Pharmaceuticals has entered into a definitive agreement to acquire BlueJ Therapeutics for $250 million in cash, $370 million in Mirum stock (priced at $71.21 per share), and up to $200 million in tiered sales-based milestone payments.
- The acquisition adds tegovibart, an anti-hepatitis B surface antigen monoclonal antibody for chronic hepatitis delta virus (HDV), to Mirum's pipeline. Tegovibart has received FDA Breakthrough Therapy and EU PRIME designations based on compelling Phase II results.
- The transaction is expected to close in the first quarter of 2026 and is being funded in part by a concurrent $200 million private placement financing.
- Tegovibart is currently in a Phase III program (Azure studies), with interim data from Azure One expected in Q2 2026 and final data from Azure One and Four expected in the second half of 2026 to support a potential BLA submission in the first half of 2027.
- Mirum anticipates tegovibart has a global revenue potential of at least $750 million, contributing to an overall rare disease portfolio revenue potential of over $4 billion.
Dec 8, 2025, 1:30 PM
Mirum Pharmaceuticals Announces Proposed Acquisition of Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals has announced the proposed acquisition of Bluejay Therapeutics, with the transaction expected to close in Q1 2026.
- The acquisition is valued at $250 million in cash and $370 million in stock (issued at $71.21 per share), with potential additional payments of up to $200 million in tiered sales milestones.
- This strategic move is expected to enhance Mirum's position in rare liver disease by integrating Brelovitug, Bluejay's Hepatitis Delta Virus (HDV) treatment, which has an estimated $750 million+ revenue potential.
- Mirum plans to fund the acquisition with a $200 million private placement at $68.48 per share, while maintaining its financial independence.
Dec 8, 2025, 1:30 PM
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Hepatitis D Treatment
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals has entered into a definitive agreement to acquire Bluejay Therapeutics for an upfront payment of $620 million, consisting of $250 million in cash and $370 million in Mirum stock, with potential additional sales-based milestone payments of up to $200 million.
- The acquisition aims to integrate brelovitug, Bluejay's late-stage drug for chronic hepatitis delta virus (HDV), into Mirum's portfolio; brelovitug is currently in a Phase 3 registrational study with results anticipated in late 2026 and a potential market launch in 2027.
- Chronic hepatitis D is a severe liver disease with no current approved therapies, affecting approximately 230,000 people in the US and Europe.
- Mirum has secured a $200 million private placement to fund clinical development and commercialization, with the transaction expected to close in the first quarter of 2026.
Dec 8, 2025, 1:12 PM
Mirum Pharmaceuticals Announces Definitive Agreement to Acquire Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
- Mirum Pharmaceuticals, Inc. entered into a definitive agreement on December 6, 2025, to acquire Bluejay Therapeutics, a privately held biotechnology company, in a transaction anticipated to close in Q1 2026.
- The acquisition includes worldwide rights to brelovitug, a late-stage monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV).
- The deal is valued at an upfront payment of $250 million in cash and up to 5,196,009 shares of common stock (approximately $370 million), with additional milestone payments of up to $200 million in cash.
- Brelovitug is in the AZURE Phase 3 registrational program for HDV, with top-line data from AZURE 1 and AZURE 4 expected in 2H 2026, and potential BLA submission and launch in 2027. Mirum estimates brelovitug's worldwide total annual revenue potential in HDV to be more than $750 million.
Dec 8, 2025, 1:00 PM
Mirum Pharmaceuticals Provides 2025 Revenue Guidance and Pipeline Updates
MIRM
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Mirum Pharmaceuticals projects $500 million-$510 million in revenues for 2025, is cash flow positive, and expects continued growth across its three approved medicines.
- The company initiated a Phase 2 trial for MRM-3379 in Fragile X syndrome, a condition estimated to represent a billion-plus opportunity.
- An interim analysis of the Volixibat study for PSC led to the continuation of the trial with the 20 milligram dose, indicating positive progress.
- Commercial growth is driven by better-than-expected identification of treatment-naive PFIC patients, contributing to outperformance against initial guidance.
- Mirum holds a significant patent extending to 2040 and is prepared to defend its intellectual property against anticipated Paragraph IV filings.
Dec 2, 2025, 7:10 PM
Mirum Pharmaceuticals Provides Business Update at HealthCONx Conference
MIRM
Guidance Update
New Projects/Investments
Legal Proceedings
- Mirum Pharmaceuticals reiterated its 2025 revenue guidance of $500 million-$510 million and confirmed it is cash flow positive, anticipating continued growth from its three approved medicines.
- The company initiated a Phase 2 trial for MRM-3379 in Fragile X syndrome, targeting a billion-plus market opportunity among an estimated 50,000 male patients in the US and Europe.
- An interim analysis for Volixibat in PSC recommended to continue the study unchanged and selected the 20 mg dose, suggesting positive efficacy and safety thresholds were met.
- Commercial performance in 2025 was significantly boosted by higher-than-expected patient identification in PFIC, a trend the company anticipates will persist.
- Mirum is prepared to vigorously defend its intellectual property, specifically its 2040 method of use patent, against expected Paragraph IV filings.
Dec 2, 2025, 7:10 PM
Mirum Pharmaceuticals Provides 2025 Revenue Guidance and Pipeline Updates
MIRM
Guidance Update
New Projects/Investments
Legal Proceedings
- Mirum Pharmaceuticals provided 2025 revenue guidance of $500 million-$510 million and expects continued growth from its three approved medicines, noting it is cash flow positive.
- The company announced the enrollment of the first patient in a Phase 2 trial for MRM-3379 for Fragile X syndrome, a market estimated to be a billion-plus opportunity with approximately 50,000 male patients in the U.S. and Europe.
- An interim analysis for the Volixibat PSC trial resulted in the study continuing unchanged, with the 20 milligram dose selected for its therapeutic window.
- Mirum outperformed its original 2025 guidance, primarily driven by identifying more naive PFIC patients than anticipated.
- The company is prepared to vigorously defend its 2040 method of use patent against expected Paragraph IV filings.
Dec 2, 2025, 7:10 PM
Quarterly earnings call transcripts for Mirum Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more